Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PQRI sends first proposal to FDA

This article was originally published in The Tan Sheet

Executive Summary

Agency urged to "allow stratified sampling and testing of in-process dosage units to demonstrate blend uniformity in all production batches as an alternative to blend analysis," Product Quality Research Institute announces April 5. PQRI suggests option to satisfy agency's GMP requirement that firms need to demonstrate "adequacy of mixing to assure uniformity and homogeneity." Final proposal was presented to PQRI steering committee in December (1"The Tan Sheet" Dec. 10, 2001, p. 23). FDA will evaluate recommendation, either adopt it or provide scientific explanation why the proposal is lacking, PQRI says...

You may also be interested in...



Blend Uniformity Guidance Withdrawn In Face Of PQRI Recommendations

FDA has withdrawn a draft guidance that established in-process acceptance criteria related to blend uniformity analysis for certain drugs

Stratified Sampling In Blend Uniformity Testing Advocated By PQRI

Stratified sampling should be used to demonstrate blend and dosage unit content uniformity, PQRI's Blend Uniformity Working Group has concluded

Amarin's Vascepa May Face Generic Competition In US Next Year After Patents Ruled Invalid

Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.

Topics

UsernamePublicRestriction

Register

PS093892

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel